

Perfluorooctane sulfonate

Miralles-Marco, Ana; Harrad, Stuart

DOI:

[10.1016/j.envint.2015.02.002](https://doi.org/10.1016/j.envint.2015.02.002)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Miralles-Marco, A & Harrad, S 2015, 'Perfluorooctane sulfonate: A review of human exposure, biomonitoring and the environmental forensics utility of its chirality and isomer distribution', *Environment International*, vol. 77, pp. 148-159. <https://doi.org/10.1016/j.envint.2015.02.002>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

After an initial embargo period this document is subject to the terms of a Creative Commons Attribution Non-Commercial No Derivatives license

Checked October 2015

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

1 **Perfluorooctane sulfonate: A review of human exposure, biomonitoring**
2 **and the environmental forensics utility of its chirality and isomer**
3 **distribution**

4

5 **Ana Miralles-Marco*, Stuart Harrad**6 Division of Environmental Health and Risk Management, School of Geography, Earth, and
7 Environmental Sciences, University of Birmingham, Birmingham B15 2TT, U.K.

8 * Corresponding author. Tel.: +44 121 414 5431; E-mail: a.miralles-marco@bham.ac.uk

9

10 **Abstract**

11 Perfluorooctane sulfonate (PFOS) found extensive use for over 60 years up until its
12 restriction in the early 2000s, culminating in its listing under the Stockholm Convention on
13 Persistent Organic Pollutants (POPs) in 2009. Efforts to minimise human body burdens are
14 hindered by uncertainty over their precise origins. While diet appears the principal source for
15 the majority of western populations, with other pathways like dust ingestion, drinking water,
16 and inhalation also important contributors; the role played by exposure to PFOS-precursor
17 compounds followed by *in vivo* metabolism to PFOS as the ultimate highly stable end-
18 product is unclear. Such PFOS-precursor compounds include perfluorooctane sulfonamide
19 derivatives, e.g. perfluorooctane sulfonamides (FOSAs) and sulfonamidoethanols (FOSEs).
20 Understanding the indirect contribution of such precursors to human body burdens of PFOS
21 is important as a significant contribution from this pathway would render the margin of safety
22 between the current exposure limits and estimates of external exposure to PFOS alone,
23 narrower than hitherto appreciated. Estimates derived from mathematical modelling studies,

24 put the contribution of so-called “precursor exposure” at between 10% and 40% of total
25 PFOS body burdens. However, there are substantial uncertainties associated with such
26 approaches. This paper reviews current understanding of human exposure to PFOS, with
27 particular reference to recent research highlighting the potential of environmental forensics
28 approaches based on the relative abundance and chiral signatures of branched chain PFOS
29 isomers to provide definitive insights into the role played by “precursor exposure”.

30 **Keywords**

31 Perfluoroalkyl sulfonate, PFOS-precursors, perfluoroalkyl substances, biomonitoring, human
32 exposure, chirality, isomer, body burdens

33

34

35 INTRODUCTION

36 Perfluoroalkyl substances (PFASs) are a family of synthetic compounds characterised by a
37 fully fluorinated hydrophobic linear carbon chain, to which are attached different hydrophilic
38 functional groups (Fromme et al., 2009). These chemicals have been manufactured since the
39 late 1940s by 3M (3M, 1999) as well as other companies like Dupont, and have been
40 produced and used in commercial products and industrial processes for over 60 years
41 (Lindstrom et al., 2011). PFASs possess low molecular polarisability, short C–F bond length,
42 and large C–F bond binding energy. Such characteristics govern the oil and water repellency,
43 physical and chemical stability, and surfactant properties of PFASs (Zushi et al., 2012).
44 These properties mean that PFASs have found wide use in a variety of applications, with
45 historic production peaking at the end of the 20th century in North America and Europe (Paul
46 et al., 2009). In an environmental context however, the strong C-F bond means that PFASs
47 are resistant to thermal, chemical and biological degradation (Kissa, 2001) and are capable of
48 bioaccumulation and long-range environmental transport, exemplified by their detection in
49 the Arctic (Chaemfa et al., 2010; Sonne, 2010; Zhao et al., 2012). As a result, PFOS and its
50 salts, as well as perfluorooctane sulfonyl fluoride (POSF) were in 2009 listed as persistent
51 organic pollutants (POPs) under the Stockholm Convention (Geneva: Stockholm Convention
52 Secretariat, 2009). POSF can degrade to PFOS directly or indirectly through chemical or
53 enzymatic hydrolysis, and hence POSF-derived products can be degraded ultimately to PFOS
54 (Zhao et al., 2012).

55 PFAS synthesis routes have been well described by Lehmler et al. (2005). The two main
56 processes are electro-chemical fluorination (ECF) (3M, 1999), and telomerisation (Schultz et
57 al., 2003), with PFOS, and PFOS salts synthesised via ECF. It is important to note here that a
58 number of possible PFOS isomers exist in POSF based mixtures (in which process PFOS
59 impurities are present between 0.1 and 5% (Paul et al., 2009) due to the nature of the ECF

60 process itself). The isomer composition of the commercial PFOS products can be up to 30%
61 of total PFOS. Moreover, some of these isomers (specifically those that are branched chain)
62 are chiral, with the result that the environmental fate and behaviour of PFOS may vary
63 according to its isomeric and enantiomeric composition.

64 The main applications of PFOS and PFOS derivatives included uses in: inks, varnishes,
65 waxes, fire-fighting foams, metal plating and cleaning products, coating formulations (for
66 walls, furniture, carpeting, food packaging), lubricants, water and oil repellents for leather,
67 paper and textiles (3M, 2000). Before 2003, POSF was used as a raw material for the
68 synthesis of PFOS (among other perfluorooctane sulphonamide derivatives) (Burk et al., 2011).
69 However, 3M Company replaced PFOS with perfluorobutane sulfonate (PFBS) after 2003,
70 because the former was considered harmful to the environment (Renner, 2006).

71 Over the last 15 years, a substantial weight of evidence has emerged concerning
72 environmental contamination with PFOS, consequent human exposure, and its effects. This
73 paper reviews this evidence, and summarises recent developments that exploit the chirality
74 and relative abundance of branched chain PFOS isomers to provide valuable insights into the
75 environmental fate and behaviour of PFOS and its precursors.

76

77 **SOURCES, PRODUCTION AND APPLICATIONS**

78 The history of PFAS production is difficult to portray accurately due to the proprietary nature
79 of this information (Lindstrom et al., 2011), but the 3M Company was the first main producer
80 of POSF (an intermediate product for the synthesis of PFOS) with the total cumulative
81 production estimated to be approximately 96,000 t in the peak years between 1970 and 2002
82 (Paul et al., 2009). In 2002, the 3M Company discontinued its production; however other
83 companies commenced manufacture at this point to meet existing market demands, with an

84 estimated 1,000 t being produced annually since 2002 (Paul et al., 2009). In addition to the
85 3M production facilities in the USA, another 6 plants were located in Europe (4 in EU
86 member states), 6 in Asia (of which 4 were in Japan) and one in South America (Paul et al.,
87 2009).

88 The main way of synthesising PFASs is ECF. In this process, a straight chain hydrocarbon is
89 reacted with H and F atoms and electricity to substitute all of the hydrogen atoms with
90 fluorine (Kissa, 2001). This constitutes the main process of POSF synthesis, generating about
91 70% of the straight chain product with the remainder comprised of branched and cyclic
92 isomers. POSF can then be used in a series of reactions via N-methyl and N-ethyl
93 perfluorooctane sulfonamide (N-MeFOSA and N-EtFOSA) to yield N-methyl and N-ethyl
94 perfluorooctane sulfonamidoethanols (N-MeFOSE and N-EtFOSE), which historically were
95 used to produce polymeric materials and phosphate esters respectively, and used on surface
96 coatings for textiles and paper products (Paul et al., 2009; Olsen et al., 2005, D'Eon and
97 Mabury, 2011).

98 The major applications of POSF derivatives have been: (1) in carpets to impart stain and dirt
99 repellence, (2) in apparel to provide water repellence, (3) in paper and packaging to afford oil
100 and grease repellence, (4) in performance chemicals such as hydraulic fluids for aviation, and
101 (5) in aqueous fire-fighting foams (AFFFs). AFFFs are perhaps the most prominent method
102 of widespread environmental dispersal, with use for oil drilling and military fire-fighting
103 practice (Paul et al., 2009).

104 All compounds produced from POSF are widely referred to as “PFOS equivalents” or just
105 “PFOS”, due to their collective potential to degrade or transform into PFOS. In contrast,
106 PFOS itself is extraordinarily stable in the environment, with no known natural mechanism of
107 degradation. Hence, regulatory bodies have been working to reduce the production and use of
108 some PFASs (Zushi et al., 2012). The 3M company, together with the US Environmental

109 Protection Agency (USEPA) resolved to decrease the production of PFOS and related
110 compounds between 2000 and 2002 (3M, 2008). At the same time, Significant New Use
111 Rules (SNUR) were also put in place (2000, 2002, and 2007) in the US, designed to restrict
112 the production and use of materials that contained PFOS or its various precursors. The EPA
113 then worked with eight leading chemical companies in the 2010-2015 PFOA Stewardship
114 Program to reduce emissions and residual content of PFOA and long-chain PFCAs by 95%
115 by 2010, with the long-term goal to work towards elimination of long-chain PFCAs by 2015
116 (USEPA, 2010).

117 Within the EU, PFOS and its derivatives are regulated on the market or only used as a
118 substance or constituent of preparations listed as permissible in the EU Directive (2006).
119 Under this directive, PFOS may still be used in applications that are deemed un-substitutable,
120 including photolithographic processes, photographic coatings, mist suppressants for non-
121 decorative hard chromium (VI), plating/wetting agents in controlled electroplating systems
122 (pollution prevention and control are required), and hydraulic fluids for aviation. Such
123 regulation started within the EU in June 2008 (Zushi et al., 2012).

124 The presence of PFOS in the environment has been attributed to two major sources: direct
125 and indirect (Armitage et al., 2009; Prevedouros et al., 2006; Paul et al., 2009). Direct sources
126 are derived from the manufacture and application of PFOS and POSF (Paul et al., 2009). By
127 comparison, indirect sources are a consequence of chemical reaction impurities or breakdown
128 of so-called precursors such as N-Me-FOSE and N-Et-FOSE. It has been estimated that 85%
129 of indirect emissions occur via release from consumer products during use and disposal (3M,
130 2000).

131

132 **HEALTH CONCERNS**

133 General toxicological findings associated with laboratory animals exposed to PFOS include
134 hepatomegaly and hepatic peroxisome proliferation, liver, testicular (Leydig cell), and
135 pancreatic (acinar cell) tumours, reproductive and developmental deficits, neurotoxicity, and
136 immunotoxicity (DeWitt et al., 2012).

137 Most of the reported studies concerning PFOS toxicity have been conducted on mice, with
138 subsequent extrapolation to humans of observed murine effects complicated by interspecies
139 variability in toxicokinetics. Even gender and ethnic origin can play a role (Kato et al., 2011).
140 Adverse effects attributed to PFOS in rodents include decreased body weight, increased liver
141 weight, and a steep dose-response curve for mortality (Seacat et al., 2003), as well as an
142 increase in hepatocellular and follicular cell adenomas at high exposure levels (3M, 2002).

143 Human studies carried out on workers occupationally exposed to PFAS have generally
144 yielded inconsistent results. While such workers have circulating blood levels of PFAS that
145 are hundreds of times those of non-occupationally exposed individuals (Olsen et al., 2003;
146 Steenland et al., 2010), it is difficult to determine conclusive results in these studies (either
147 positive or negative) because sample populations are small, historical exposure levels are
148 uncertain, individuals often have had simultaneous exposures to other compounds, and they
149 may have pre-existing conditions that complicate evaluations (Fletcher et al., 2013).

150 Compared to PFOS, studies of PFOA exposed workers are more numerous. Several studies
151 have shown a positive association between PFOA exposure and cholesterol, which could
152 have implications for the development of cardiovascular disease. PFOA has also been
153 associated with elevated uric acid levels, which may in turn lead to hypertension and
154 cerebrovascular disease (Lindstrom et al., 2011; Olsen et al., 2003; Costa et al., 2009; Sakr et
155 al., 2007).

156 Based on the toxicological evidence available to date, chronic exposure guidelines are being
157 developed for PFOS and PFOA by the USEPA and other jurisdictions for water and food, but

158 little has been done thus far for other PFASs. A review of current global guidelines and
159 regulations can be found in Zushi et al. (2012), and some especially pertinent illustrative
160 examples are discussed briefly here. The continuing uncertainty surrounding the human
161 health impacts of PFASs is reflected in the disparity between the values promulgated by
162 different jurisdictions. The risk from PFOS for human adults has been evaluated as low based
163 on the Margin of Exposure (MOE), derived from the ratio of the provisional tolerable daily
164 intakes (pTDI) and the level of intake (Zushi et al., 2012). Fromme et al. (2009) estimated the
165 average (and high end) daily intake of PFOS and PFOA, including the indirect contribution
166 from their precursors, as 1.6 (11.0) and 2.9 (12.7) ng/kg bw/day, respectively. These
167 exposures are comfortably lower than the pTDIs for the general adult population of 100 ng/kg
168 bw/day for PFOS and 3000 ng/kg bw/day for PFOA, promulgated by the German Federal
169 Institute for Risk Assessment (BfR) and the UK Committee on Toxicity of Chemicals in
170 Food, Consumer Products and the Environment (COT) respectively. Moreover, the USEPA
171 issued provisional short-term health advisories for PFOS (200 ng/L) and PFOA (400 ng/L) in
172 drinking water, on the assumption that short-term consumption below these levels will
173 safeguard public health (USEPA, 2009).

174 In a parallel approach to limit values for external exposure via ingestion of food and water,
175 the Biomonitoring Commission of the German Federal Environmental Agency used the 95th
176 percentile concentration values of two German studies (Midasch et al., 2006; Fromme et al.,
177 2007b), to establish reference values for PFOA and PFOS in plasma of children and adults.
178 These reference values specify a maximum permissible presence of PFOS of 10 µg/L for
179 children, 20 µg/L for adult females, and 25 µg/L for adult males (Wilhelm et al., 2009).

180

181 **HUMAN EXPOSURE**

182 The first report of the presence of PFOS, PFOA, and other PFASs in samples of human blood
183 purchased from biological supply companies emerged in 2001 (Hansen et al., 2001), although
184 the first paper regarding the presence of organofluorine compounds in biological samples
185 dates from 1968 (Taves, 1968). Since then, a considerable database concerning human
186 exposure to PFASs has emerged. The following section summarises current understanding of
187 this topic with particular reference to PFOS.

188 **Human Biomonitoring Data**

189 With respect to human biomonitoring, concentrations of PFAS in human blood (whole blood,
190 plasma and serum) in the general population have been reviewed recently (Angerer et al.,
191 2011; Fromme et al., 2009) (*Table 1*). Most human biomonitoring studies are not carried out
192 on whole blood, but on serum. The first reported concentrations of PFOS in blood were
193 published by Hansen et al. (2001). This study showed 100% of the blood samples contained
194 PFOS at concentrations ranging from 6.7 to 81.5 ng/mL. Following this seminal report,
195 concern about how PFOS enters and remains in the human body increased, leading to the
196 publication of a number of studies, each based on the analysis of a large number of blood
197 samples. Amongst the most relevant of these are those of Calafat et al. and Kato et al.
198 (Calafat et al., 2007a and 2007b; Kato et al., 2011) in the North American population, which
199 each discuss results from the National Health and Nutrition Examination Surveys (NHANES)
200 carried out by the US Center for Disease Control and Prevention, and published in the Fourth
201 National Report on Human Exposure to Environmental Chemicals (CDC 2009; CDC 2013).
202 In these reports, the presence of a range of chemical contaminants is studied in blood and
203 urine from the general population of the USA. The PFOS measurements reported in the two
204 papers from Calafat et al. refer to the NHANES results from 1999-2000 and 2003-2004, and
205 are based on 1,562 and 2,094 serum samples, with a detection frequency (DF) > 96% for
206 PFOS in both studies, and geometric means of 21.1 and 20.7 ng/mL respectively. One of the

207 studies (Calafat et al., 2007b), also reported that geometric mean PFOS levels declined by
208 32% between 1999/2000 and 2003/2004. Moreover, the most recent (2007/2008) NHANES
209 results (Kato et al., 2011), indicate that PFOS concentrations continue to decline (exemplified
210 by a geometric mean of 13.2 ng/mL). This follows an earlier report (Olsen et al., 2007b) of a
211 decrease on PFOS levels in human blood in the general American population, from a
212 geometric mean of 33.1 ng/mL in samples collected in 2000, to 15.1 ng/mL in samples
213 collected in 2005. A second study (Olsen et al., 2008) based on a large number of human
214 blood samples (around 600), highlighted that the observed ~60% decline in PFOS was
215 consistent with its elimination half-life and the time period since the phase-out of POSF by
216 3M in 2000-2002. Combined, these studies suggest that restrictions on the production and use
217 of PFOS have led to reductions in human exposure in the US, although it remains in the
218 environment, wildlife and the US population (CDC, 2009). Other US studies document
219 similar PFOS concentrations in blood, but can not provide evidence of a temporal trend.
220 Specifically, Hansen et al. (2001), as well as Olsen et al. (2005), published results in which
221 median PFOS concentrations were 26.2 and 34.7 ng/mL for samples taken in the late
222 1990s/early 2000s (exact sampling dates not given) and 1974/1989 respectively. This
223 apparent increase in human exposure in the immediate aftermath of the 2002 voluntary
224 cessation of production by 3M, may be attributed to variation in the respective populations
225 sampled in the two studies.

226 An important point is that – in line with Taniyasu et al., 2003 - the values in *Table 1* include
227 data for both serum and whole blood. This approach is preferred here to the alternative format
228 employed by others (e.g. Yeung et al. (2006) and Kannan et al. (2004)) whereby
229 concentrations in whole blood were converted to concentrations in serum by multiplying
230 whole blood concentrations by 2, to allow comparison across different studies. This
231 conversion becomes even more sensitive when analysing PFOS precursors, due to their

232 different distribution between serum and blood (Martin et al., 2010). Notwithstanding the
233 influence of serum versus whole blood basis concentrations, examination of the global
234 database between 2004 and 2007, reveals some differences in both median and maximum
235 PFOS concentrations in human blood recorded in different studies shown in *Table 1*. Likely
236 causes of these between-study variations in the concentrations of PFOS include: international
237 variations in use and exposure, as well as variations between sampled populations in lifestyle,
238 age, ethnicity, and gender (Kato et al., 2011). While such differences in absolute
239 concentrations of PFOS exist, they are not as marked as those observed for other halogenated
240 persistent organic pollutants like polybrominated diphenyl ethers (Hites, 2004).

241 *Table 2* reveals that, in addition to blood, human milk is being monitored increasingly. This
242 shift towards monitoring milk may be attributed to its less invasive nature, greater sample
243 availability and mass, recent improvements in the sensitivity and accuracy of ultra-trace
244 analytical techniques (although these are likely still worse than for serum), and the dual role
245 of human milk as an indicator of both the donor's body burden, and dietary intake of nursing
246 infants. Of course, this is offset to some degree by the fact that human milk as a
247 biomonitoring tool is restricted to a specific sector of the population. Moreover, comparing
248 *Tables 1* and *2*, it is apparent that concentrations of PFOS in human blood exceed those in
249 human milk. Several studies of human milk have been carried out since the first published
250 reports. Most such studies show detection frequencies (DF) > 90%, except those of
251 Bernsmann and Fürst (2008) (DF of 66% in Germany), and Guerranti et al. (2013), in which
252 the detection frequency was below 50% (DF of 41% in Italy). Median concentrations range
253 from 0.04 to 0.33 ng/mL, except for the study of Roosens et al. (2010) for the Flemish
254 general population, who reported a median concentration an order of magnitude higher than
255 other studies (2.9 ng/mL). Some of the samples reported by Roosens et al. (2010) were
256 collected from donors living near a PFOS production facility, for which the authors also

257 reported high concentrations of PFOS in serum. Elevated concentrations of PFOS had also
258 been reported previously in biota from the same location by Dauwe et al. (2007).

259 In contrast to blood and milk, only a small number of papers have reported concentrations of
260 PFASs in other human matrices such as: liver, seminal plasma, and umbilical cord blood
261 (Apelberg et al., 2007; Guruge et al., 2005; Inoue et al., 2004; Kärman et al., 2007a;
262 Kuklenyik et al., 2004; Midasch et al., 2007; Olsen et al., 2003; So et al., 2006).

263 Scientific understanding of the origins of and influences on the presence of PFOS in humans
264 is complicated by a number of factors (Lindstrom et al., 2011). Just as environmental
265 degradation of PFOS precursors constitutes an important indirect source of PFOS
266 contamination of the ambient environment; external exposure to PFOS precursors followed
267 by *in vivo* metabolism, has been identified as a potentially substantial indirect contributor to
268 human body burdens of PFOS (Trudel et al., 2008; Vestergren et al., 2008). Such indirect
269 pathways are distinct from direct exposure via human contact with and uptake of PFOS itself.
270 Moreover, PFOS (as well as other long chain PFASs) tend to accumulate in the human body
271 with an estimated half-life of around 5 years (Olsen et al., 2007a). This slow elimination from
272 the human body hampers efforts to determine how changes in lifestyle, diet, or other
273 exposure-related factors influence blood levels. Notwithstanding this, while age has been
274 suggested to exert little influence on circulating PFAS concentrations, with inconsistent
275 results in cross-sectional studies (Haug et al., 2009; Harada et al., 2007), age associations
276 could be consistent with dietary exposure in a post phase out situation (Nøst et al., 2014).
277 However, as highlighted above, gender and ethnicity do seem to influence the accumulation
278 of some compounds. In a recent paper, Kato et al. (2011) attributed differences in human
279 body burdens between ethnic groups to ethnic differences in exposure related to lifestyle, the
280 use of products containing PFASs, and diet. Meanwhile, gender-related differences in body
281 burden (lower concentrations in women than men) have been attributed to physiological

282 differences (i.e. accumulation and elimination), as well as pregnancy, lactation and
283 menstruation (Harada et al., 2004).

284

285 **Direct Pathways of Human Exposure to PFOS**

286 Non-occupational exposure to PFOS is thought to occur via the ingestion of food and
287 drinking water, as well via inhalation and contact with indoor dust.

288 *Drinking water.* Data concerning concentrations of PFOS in drinking water are rather limited,
289 and all published studies report concentrations in the ng/L range (see *Table 3*). Initially, Saito
290 et al. (2004) reported PFOS concentrations in tap water from Japan to fall between 0.1 and
291 12.0 ng/L. Later studies (Lange et al., 2007; Ericson et al., 2009; Skutlarek et al., 2006;
292 Tanaka et al., 2008) have reported higher concentrations however; up to 58 ng/L and 143
293 ng/L PFOS in tap water from Spain (Ericson et al., 2009) and Japan (Tanaka et al., 2008)
294 respectively. Overall, PFOS is one of the most frequently detected PFASs (together with
295 PFOA) in drinking water, with detection frequencies varying between 40 and 100% in
296 published papers. Reassuringly, maximum values reported in drinking water to date, fall
297 below the USEPA's short term advisory limit concentration for drinking water of 200 ng/L
298 PFOS.

299 *Indoor air and dust.* In addition to drinking water; recent investigations show the indoor
300 environment is a potentially important contributor to human exposure to PFASs including
301 PFOS (D'Hollander et al., 2010; Fromme et al., 2009; Goosey and Harrad, 2011; Haug et al.,
302 2011a). The first paper concerning PFOS contamination of indoor dust was published in
303 2003, by Moriwaki et al. (*Table 4*). Sixteen samples of house dust were analysed, containing
304 concentrations of PFOS between 11 and 2,500 ng/g. Since then, similar studies have been
305 carried out in Canada, Japan, Sweden, USA, Australia, the UK, and Spain, with wide

306 variation in concentrations found. While Bjorklund et al. (2009) reported concentrations of
307 PFOS in dust from 10 houses in Sweden in 2009 to range between 15 and 120 ng/g, Strynar
308 et al. (2008) and Kato et al. (2009) reported substantially higher concentrations, ranging
309 between 8.9 and 12,100 ng/g in the USA, and 2.6 and 18,000 ng/g in Australia. Median
310 concentrations further reflect international variations, being 38 ng/g for the Swedish study,
311 and 201 ng/g and 480 ng/g for the Canadian and Australian surveys respectively. Moreover,
312 Goosey and Harrad (2011) also reported statistically significant differences ($p < 0.05$) between
313 concentrations of PFOS in dust from different countries. Specifically, UK, Australia, Canada,
314 France, Germany, and US > Kazakhstan; and UK, Australia, Canada, and US > Thailand.
315 They attributed such differences to lower use of products containing PFAS in Kazakhstan and
316 Thailand compared to Europe, North America, and Australia.

317 Moreover, recent studies have reported concentrations of PFOS and other PFAS in indoor air
318 (principally vapour phase, but with some particulate phase compounds incorporated) (Ericson
319 Jogsten et al., 2012; Goosey and Harrad, 2012; Shoeib et al., 2011). In these, PFOS was the
320 most prevalent PFAS, with a wide range of concentrations between countries (for example,
321 lower values detected in Spain, higher in the UK). The frequency of detection for PFOS in
322 indoor air is more variable than for dust (in air the range is from 0% to 100% c.f. 60% to
323 100% for dust).

324 *Outdoor air.* Outdoor air has also been studied, sometimes in conjunction with indoor air.
325 Shoeib et al. (2005) reported PFAS concentrations in outdoor air were 1 or 2 orders of
326 magnitude lower than in indoor air, as data from more recent studies in *Table 5* corroborate.
327 This is consistent with the hypothesis that substantial indoor sources of PFOS exist, with the
328 result that indoor air likely exerts an appreciable influence on outdoor atmospheric
329 contamination. While this would logically lead to higher atmospheric concentrations of PFOS
330 in conurbations due to higher urban building densities; Barber et al. (2007) reported higher

331 detection frequencies of PFAS (including PFOS) than expected in outdoor air from rural
332 areas. Such findings suggest the environmental distribution of PFAS is complex, and that
333 indoor environments are not the only driver influencing outdoor contamination.

334 *Diet.* Overall, based on the exposure models and reviews published to date (D'Eon and
335 Mabury 2011; Ericson-Jogsten et al, 2012; Fromme et al., 2009; Trudel et al., 2008;
336 Vestergren et al., 2008); food contaminated via bioaccumulation, has been suggested by
337 several authors as the principal pathway of direct human exposure to PFOS; (D'Hollander et
338 al., 2010; Fromme et al., 2007a; Trudel et al., 2008; Kärman et al., 2009; Vestergren et al.,
339 2008; Fromme et al., 2009, Herzke et al., 2013).

340 In 2012, Ericson-Jogsten reported diet as the main pathway of PFOS exposure for adults and
341 toddlers from Catalonia, Spain (constituting more than 70% of the daily total intake).
342 Ingestion of water was identified as the second most important human exposure pathway,
343 with inhalation of air and ingestion of dust considered negligible (< 0.5% of the total intake).
344 An alternative Scenario-Based Risk Assessment approach (SceBRA) (Scheringer et al., 2001)
345 was used in the studies of Trudel et al. (2008) and Vestergren et al. (2008). Both studies
346 reported food ingestion as one of the most important pathways under three different exposure
347 scenarios, although there was some divergence between the two studies about the absolute
348 contribution of diet. Moreover, house dust ingestion was identified as a significant direct
349 exposure pathway in both studies (though different absolute values of its proportional
350 contribution to overall exposure were reported); while for some other pathways, e.g. direct
351 hand contact with carpets treated with products containing PFOS and subsequent oral
352 ingestion, assessment of their importance differs substantially between studies. Future
353 evaluations of the relative contributions of different pathways to overall exposure to PFOS,
354 will benefit from recent and on-going improvements in analytical techniques that permit
355 detection of PFOS in foodstuffs and other exposure matrices at lower levels.

356

357 **Indirect sources of human exposure to PFOS**

358 As highlighted above, POSF-derived substances may be metabolised *in vivo* to PFOS,
359 constituting a substantial indirect source of human exposure to PFOS. The POSF-derived
360 substances in question represent a vast array of structures with the general formula
361 C₈F₁₇SO₂NRR', that are referred to generically as "PFOS-precursors" (or "PreFOS" in some
362 literature, such as Asher et al., 2012). Consequently, as described by Prevedouros et al.
363 (2006), and Ross et al. (2012), two general routes of exposure may occur: (1) direct exposure
364 to PFOS, through diet, inhalation, and contact with contaminated settled dust (either by
365 ingestion or dermal contact), and (2) exposure to PFOS-precursors, followed by their
366 biotransformation in the body to PFOS. The main PFOS-precursor substances and its salts are
367 listed in *Table 6*.

368 PFOS-precursors are mainly degraded to PFOS by *in vivo* metabolic processes (Martin et al.,
369 2010; Xu et al., 2004). Some PFOS-precursors like N-Et-FOSA and N-Et-FOSE, have shown
370 low conversion factors < 1% in rats and trout (Xu et al., 2004; Tomy et al., 2004) or have not
371 yet been studied. However, in 2003, Seacat et al. reported a conversion factor to PFOS of up
372 to 20% in a study where rats were exposed long term to N-Et-FOSE; an observation
373 confirmed subsequently by Xie et al. (2009). Although the reported levels of PFOS-
374 precursors are generally lower and their physicochemical properties differ from those of
375 PFOS, a variety of them have been detected in water (Ahrens et al., 2009), in indoor and
376 outdoor air (Shoeib et al., 2005; Jahnke et al., 2007), in packaged food (Tittlemier et al.,
377 2006), and in live organisms (from mussels to bald eagles) and waterbird eggs (Kannan et al.,
378 2005; Wang et al., 2008). One of the most measured PFOS-precursors is
379 perfluorooctanesulfonamide (PFOSA), which is a stable intermediate in the pathway of
380 PFOS-precursor degradation to PFOS, and whose structure is depicted in *Fig. 1*.

381 Perfluorinated sulfonamide based products (PFSAm) are also important, as their production is
382 associated with the presence of FOSAs and FOSEs as degradation or residual products.
383 Positive correlations between the concentrations of PFOSA and PFOS have been found in
384 biological samples (e.g. Martin et al., 2004) suggesting that PFOSA, and maybe other PFOS-
385 precursors, can be important contributors to body burdens of PFOS in animal species (Asher
386 et al., 2012).

387 As mentioned above, recent papers have examined the utility of human exposure models to
388 evaluate the contribution of indirect exposure pathways to human body burdens of PFOS
389 (Vestergren et al., 2008; D'Eon and Mabury 2011; Fromme et al., 2009; Gebbink et al.,
390 2015). Such studies are still quite limited in number, but their general consensus is that the
391 significance of indirect sources in driving human body burdens of PFOS should be taken into
392 account, or even had hitherto been underestimated (e.g. D'Eon and Mabury (2011)). This
393 becomes even more important in the wake of the 3M phase out, as while direct sources of
394 PFOS exposure are expected to decrease in the general population, indirect sources stemming
395 from continued use of PFOS-precursors remain. Vestergren et al. (2008) suggested the
396 relative contributions of direct and indirect exposure were dependent on the level of
397 exposure. While under low and intermediate exposure scenarios, direct dietary exposure
398 appeared the principal pathway, intake of PFOS under a high-end exposure scenario was
399 dominated by indirect precursor exposure via indoor dust (41-68%), and indoor air (10-19%).
400 The study of Gebbink et al. (2015) considered comparable pathways of exposure to those
401 studied by Vestergren et al. However, total exposure in the Gebbink et al study was 1-2
402 orders of magnitude lower, with indirect exposure to PFOS making higher and lower
403 contributions to overall exposure under low (11%) and high (33%) exposure scenarios
404 respectively than estimated previously. Gebbink et al. attributed the differences between their
405 observations and those of previous studies, to their use of recent data reporting lower levels

406 of PFOS and PFOS-precursors in human diet (Ullah et al., 2014). However, other reasons
407 such as the use of more recently published biotransformation factors describing the
408 conversion of precursors, as well as the development of more sensitive analytical methods
409 were identified as causes of the lower exposure estimates. Moreover, D'Eon and Mabury
410 (2011) critically reviewed the contribution of PFOS precursors to observed body burdens of
411 PFOS, and suggested that studies to date may underestimate the contribution of such indirect
412 exposure. This was principally due to the fact that such studies consider indirect exposure to
413 occur only as a result of exposure to PFOS precursors present as impurities or residual
414 products from the manufacture of PFOS, but do not include exposure arising from
415 manufacture and use of the precursors themselves.

416 In summary, studies to date suggest strongly that indirect exposure to PFOS makes an
417 important contribution to human body burdens. However, such studies are not yet conclusive.
418 For example, estimates of the contribution of such exposure varies between 10% and 70% of
419 the daily intake of PFOS in the studies of Verstergren et al. (2008) and Gebbink et al. (2015)
420 (based on the three different scenarios) and Fromme et al. (2009). Such variation is
421 attributable to inherent uncertainties in pivotal parameters such as the estimated efficiency of
422 precursor metabolism to PFOS. At the current time, efforts must focus on addressing: (1) the
423 lack of data on the toxicokinetics of various PFOS-precursor compounds in animals, (2) the
424 difficulty in extrapolating rodent data to humans, and (3) the fact that many commercially
425 relevant PFOS precursors have yet to be determined in any sample (Martin et al., 2010).
426 Overall, the uncertainties associated with studies to date, highlight a clear need for alternative
427 approaches, and a small but growing number of studies suggests that exploitation of the chiral
428 properties of some PFOS isomers and their precursors may constitute one such approach
429 (Wang et al., 2009; Liu et al., 2015).

430

431 **Isomer patterns and chirality of PFOS and its precursors – environmental forensic**
432 **tools?**

433 Historically, Σ PFOS has been quantified together (*see Tables 1 to 5*). Recently however, new
434 approaches (discussed further below) have been suggested as biomarkers of
435 exposure and applied in efforts to differentiate between direct exposure to PFOS and PFOS-
436 precursor exposure (Benskin et al., 2009; Martin et al., 2010).

437 *Isomer profiles.* As described above, the processes via which PFOS precursors (i.e. POSF)
438 are manufactured, are expected to produce about 70% of the linear isomer, with the
439 remaining 30% made up of a mixture of various branched chain isomers. In contrast, due to
440 preferential retention of linear PFOS in humans and rats, PFOS isomer profiles in animal
441 species are expected to comprise <30% branched chain isomers. While this holds true for
442 species such as fish and gulls for which $\geq 90\%$ of PFOS is the linear isomer (Asher et al.,
443 2009; Gebbink and Letcher, 2010; Houde et al., 2008) (*Table 7*); in some human samples, the
444 proportion of branched chain isomers can be 40-50% (Kärroman et al., 2007b; Zhang et al.,
445 2013; Beesoon et al., 2011, Liu et al., 2015). Moreover, an *in vitro* study using human
446 microsomes has showed branched chain PFOSAs to be preferentially metabolised to PFOS
447 relative to linear PFOSA (Benskin et al., 2009). This provides further evidence that precursor
448 exposure may account for human PFOS isomer profiles that are enriched in branched chain
449 isomers. This enriched profile in some human samples has been hypothesised as providing
450 evidence of precursor exposure. Moreover, observed temporal and within-population
451 variations in the relative abundance of branched chain PFOS isomers in humans (Kärroman et
452 al., 2007a; Haug et al., 2009), may be at least partly attributable to concomitant variations in
453 precursor exposure. In fact, the study of temporal trends by Liu et al. (2015), shows the
454 percentage of branched isomers in the Swedish population has increased from 32 to 45%
455 between 1996 and 2010, suggesting that exposure to PFOS precursors is becoming more

456 important compared to direct exposure, as predicted by the theoretical models discussed
457 earlier.

458 Current evidence to support this hypothesis is not clear-cut however (Ross et al, 2012). While
459 excretion in rats of branched chain PFOSAs exceeded that of the linear isomer; a
460 corresponding increase in the relative abundance of the sum of branched chain PFOS isomers
461 was not observed in the same animals. More detailed analysis of the relative abundance of
462 individual branched chain isomers in this study suggests a more complex situation. While the
463 relative abundance in the studied rats of one branched isomer (5m-PFOS), increased relative
464 to its abundance in a commercial PFOS mixture; that of another (1m-PFOS) decreased (Ross
465 et al., 2012). This may point to a need to monitor relative abundances of individual branched
466 chain isomers rather than the sum of all such isomers, to provide more conclusive insights
467 into the relative contribution of precursor exposure. This conclusion is supported by the study
468 of Gebbink et al. (2015), where an estimated isomeric pattern of 84% linear PFOS was
469 calculated for exposure via water, diet, air and dust, that contrasts with isomer patterns
470 observed in human serum samples (Beesoon et al., 2011; Haug et al., 2009; Benskin et al.,
471 2007; Zhang et al., 2013). The potential feasibility of such a detailed isomer-specific
472 approach is demonstrated by a study of PFOS isomer distributions in gull eggs from spatially
473 distinct breeding colonies throughout the Laurentian Great Lakes (Gebbink and Letcher,
474 2010). In this study, 8 individual branched chain PFOS isomers were detected in gull eggs,
475 with spatial variations in the contribution of linear PFOS in eggs highlighted as potentially at
476 least partly attributable to location-specific variations in the PFOS precursor exposure.

477 *Chirality.* One feature of many PFOS isomers is chirality, including the environmentally
478 relevant monomethyl-branched isomers 1m-, 3m-, 4m-, and 5m- PFOS, represented in *Fig. 2*,
479 where “#m-” refers to the carbon position of the branched CF₃ group (Asher et al., 2012).
480 Chirality has environmental significance for several reasons. The enantiomers of a chiral

481 compound rotate polarised light in opposite directions, but otherwise exhibit identical
482 physical and chemical properties. Consequently, environmental, physical, and chemical
483 processes generally affect both enantiomers identically (Kallenborn et al., 2001). However,
484 different enantiomers can interact differently with other chiral molecules (enzymes or
485 biological receptors), leading to different biological and toxicological behaviour (Hühnerfuss
486 et al., 2009). Moreover, unless production of a specific enantiomer is sought, the relative
487 abundance of each enantiomer, or the enantiomer fraction (EF), (referred to thereafter as the
488 chiral signature) is equal in commercially-produced chemicals. In such cases, the two
489 enantiomers (A and B) exist in identical proportions (*eq 1*) and the chiral signature is said to
490 be racemic ($EF = 0.5$). Consequently, observations of chiral signatures that deviate
491 significantly from racemic in environmental or biological matrices are strong evidence of
492 biodegradation or metabolism, and provide a powerful tool to enhance understanding of
493 environmental processes (Lehmler et al., 2010). Specifically, in the context of elucidating the
494 relative importance of precursor exposure, the EFs of chiral isomers such as 1m-PFOS in
495 freshly-manufactured PFOS are 0.5. In contrast, a branched chain PFOS precursor (1m-
496 PreFOS) was shown to be metabolised enantioselectively by human liver microsomes (Wang
497 et al., 2009). As a result, the observation of non-racemic EFs in human serum of 1m-PFOS,
498 combined with experimental evidence that 1m-PFOS itself is not excreted enantioselectively
499 in rats (Wang et al., 2011) (see *Table 7*); represents strong evidence of a discernible influence
500 of precursor exposure on human body burdens of PFOS. Recently, Liu et al. (2015) have also
501 found non-racemic EFs in serum samples from Swedish and US population, supporting
502 previous studies by Wang et al. (2009 and 2011). Furthermore, a significant correlation
503 between %br-PFOS (i.e. the proportion of Σ PFOS that are branched chain isomers) and 1m-
504 PFOS in samples from 1996-2000 has been also discussed there, but further studies are still

505 required in view of the fact that the observed changes in EF can explain only around 40% of
506 the increment in branched isomers (Liu et al., 2015).

507

$$508 \quad \quad \quad EF=A/(A+B) \quad \quad \quad (eq. 1)$$

509

510 The above are prime examples of how knowledge of chiral signatures of PFOS isomers in
511 various environmental compartments including those pertinent to human exposure, offer
512 potentially rich insights into various aspects of the environmental fate and behaviour of PFOS
513 and its precursors. As well as helping elucidate the relative influence on human body burdens
514 of direct exposure to PFOS compared to indirect exposure via metabolism of its precursors;
515 studies of chiral organochlorine compounds indicate wider insights may also be possible. For
516 example, measurement of the chiral signatures of polychlorinated biphenyls (PCBs) and
517 organochlorine pesticides in relevant environmental matrices has enhanced understanding of
518 issues such as: the relative contribution of primary versus secondary sources to outdoor air
519 (Bidleman et al., 1998; Robson and Harrad, 2004), and the role of volatilisation from soil as a
520 source of PCBs to grass (Desborough and Harrad, 2011). Moreover, tracking chiral
521 signatures of PFOS and its precursors could lead to better understanding of toxicological
522 effects on the human body, as enantioselective toxicity may exist (Loveless et al., 2006).

523

524 **Forward look**

525 PFOS is an environmental pollutant which has been widely studied. Significant manufacture
526 of both PFOS and PFOS precursors continues today; e.g. PFOS production has increased in
527 China since 2002 (with higher reported levels of PFOS in some regions of China than in the
528 US, despite the small production volumes in China compared to reported 3M production

529 (Olsen et al., 2012)), while PFOS and PFOS-precursors are still being manufactured in
530 Europe and Asia for certain applications (UNEP, 2010; Paul et al., 2009; Zhang et al., 2013).
531 This review has highlighted the potential insights into its environmental fate that may be
532 gained from better knowledge of the isomer and enantiomer-specific behaviour of both PFOS
533 and its precursors. Despite this, at the current time, only a few papers have been published
534 reporting the relative abundance of both linear and branched PFOS isomers in the
535 environment. Even fewer papers have been published that address the chirality of PFOS and
536 its precursors. In part, this is likely due to the fact that reference standards for branched chain
537 isomers and individual enantiomers have only recently become available, and to the
538 challenging nature of existing analytical methods for their measurement, exacerbated by the
539 usually very low concentrations of individual branched chain isomers in environmental and
540 biological samples. Moreover, as yet it has only proven possible to resolve the enantiomers of
541 1m-PFOS. As this represents only 2-3% of total PFOS and ~6-10% of Σ branched chain
542 isomers (Riddell et al., 2009), there are inherent uncertainties in extrapolating findings for
543 this one isomer to others. Furthermore, while variations in precursor exposure may explain
544 variations in PFOS isomer profiles; other factors such as gender and pregnancy may also be
545 influential. Despite these obstacles, exploiting the chirality and isomer patterns of PFOS and
546 its precursors offers new opportunities to gain insights into their environmental fate and
547 behaviour, as exemplified by previous studies of other chiral organohalogenes like α -
548 hexachlorocyclohexane and PCBs. Given the potential rewards, further development,
549 validation, and carefully targeted application of analytical methods for the determination of
550 chiral signatures of PFOS isomers are necessary. They will not be a trivial task; but they
551 constitute urgent research priorities.

552

553 **ACKNOWLEDGMENTS**

554 The research for this review has received funding from the European Union's Seventh
555 Framework Programme FP7/2007-2013 under grant agreement n° 316665 (A-TEAM
556 project).

557

558 **REFERENCES**

- 559 • 3M, 1999. The Science of Organic Fluorochemistry. Accessed September 2014
- 560 ○ <http://www.fluoridealert.org/wp-content/pesticides/pfos.fr.final.docket.0006.pdf>
- 561 • 3M, 2000. Phase-Out Plan for POSF-Based Products. USEPA Docket ID OPPT-2002-
- 562 0043. Accessed September 2014
- 563 ○ [http://www.fluoridealert.org/wp-](http://www.fluoridealert.org/wp-content/pesticides/3m.may16.2000.press.release.pdf)
- 564 [content/pesticides/3m.may16.2000.press.release.pdf](http://www.fluoridealert.org/wp-content/pesticides/3m.may16.2000.press.release.pdf)
- 565 • 3M, 2002. 104 Week Dietary Chronic Toxicity and Carcinogenicity Study with
- 566 Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Rats, Final Report. U.S.
- 567 EPA Administrative Record, AR226-0956
- 568 • 3M, 2008. What is 3M Doing? Accessed September 2014
- 569 ○ http://www.solutions.3m.com/wps/portal/3M/en_US/PFOS/PFOA/Information/Action/
- 570 [tion/](http://www.solutions.3m.com/wps/portal/3M/en_US/PFOS/PFOA/Information/Action/)
- 571 • Ahrens L, Barber JL, Xie ZY, Ebinghaus R. Longitudinal and latitudinal distribution of
- 572 perfluoroalkyl compounds in the surface water of the Atlantic Ocean. Environ Sci.
- 573 Technol 2009;43:3122–3127
- 574 • Angerer J, Aylward LL, Hays SM, Heinzow B, Wilhelm M. Human biomonitoring
- 575 assessment values: Approaches and data requirements. Int J Hyg Environ Health
- 576 2011;214:348–360
- 577 • Antignac JP, Veyrand B, Kadar H, Marchand P, Oleko A, Le Bizec B, Vandentorren S.
- 578 Occurrence of perfluorinated alkylated substances in breast milk of French women and
- 579 relation with socio-demographical and clinical parameters: Results of the ELFE pilot
- 580 study. Chemosphere 2013;91:802–808
- 581 • Apelberg BJ, Witter FR, Herbstman JB, Calafat AM, Halden RU, Needham LL, Goldman
- 582 LR. Cord serum concentrations of perfluorooctane sulfonate (PFOS) and

- 583 perfluorooctanoate (PFOA) in relation to weight and size at birth. (2007) *Environ Health*
584 *Persp* 2007;115(11):1670-1676
- 585 • Armitage J, MacLeod M, Cousins IT. Modeling the global fate and transport of
586 perfluorooctanoic acid (PFOA) and perfluorooctanoate (PFO) emitted from direct sources
587 using a multispecies mass balance model. *Environ Sci Technol*. 2009;43:1134–1140
- 588 • Asher BJ, Wang Y, De Silva AO, Backus S, Muir DCG, Wong CS, Martin JW.
589 Enantiospecific Perfluorooctane Sulfonate (PFOS) Analysis Reveals Evidence for the
590 Source Contribution of PFOS-Precursors to the Lake Ontario Foodweb. *Environ Sci*
591 *Technol* 2012;46:7653–7660
- 592 • Beesoon S, Webster GM, Shoeib M, Harner T, Benskin JP, Martin JW. Isomer profiles of
593 perfluorochemicals in matched maternal, cord, and house dust samples: manufacturing
594 sources and transplacental transfer. *Environ Health Perspect* 2011;119:1659–64
- 595 • Benskin JP, Bataineh M, Martin JW. Simultaneous characterization of perfluoroalkyl
596 carboxylate, sulfonate, and sulfonamide isomers by liquid chromatography–tandem mass
597 spectrometry. *Anal Chem* 2007;79:6455–64
- 598 • Benskin JP, Holt A, Martin JW. Isomer-specific biotransformation rates of a
599 perfluorooctane sulfonate (PFOS)-precursor by cytochrome P450 isozymes and human
600 liver microsomes. *Environ Sci Technol* 2009;43(22):8566–8572
- 601 • Barber JL, Berger U, Chaemfa C, Huber S, Jahnke A, Temme C, Jones KC. Analysis of
602 per- and polyfluorinated alkyl substances in air samples from Northwest Europe. *J*
603 *Environ Monit* 2007;9:530–41
- 604 • Bernsmann T, Fürst P. Determination of perfluorinated compounds in human milk.
605 *Organohalogen Compd* 2008;70:718–721
- 606 • Bidleman TF, Jantunen LM, Harner T, Wiberg K, Wideman JL, Brice K, Su K, Falconer
607 RL, Aigner EJ, Leone AD, Ridal JJ, Kerman B, Finizio A, Alegria H, Parkhurst WJ,

- 608 Szeto SY. Chiral pesticides as tracers of air-surface exchange. *Environ Pollut*
609 1998;102:43-49
- 610 • Björklund JA, Thuresson K, De Wit CA. Perfluoroalkyl compounds (PFCs) in indoor
611 dust: concentrations, human exposure estimates and sources. *Environ Sci Technol*
612 2009;43:2276–81
- 613 • Buck RC, Franklin J, Berger U, Conder JM, Cousins IT, de Voogt P, Jensen AA, Kannan,
614 K, Mabury SA, van Leeuwen SP. Perfluoroalkyl and polyfluoroalkyl substances in the
615 environment: terminology, classification, and origins. *Integr Environ Assess*
616 *Manage.*2011;7:513–541
- 617 • Calafat AM, Kuklennyik Z, Reidy JA, Caudill SP, Tully JS, Needham LL. Serum
618 concentrations of 11 polyfluoroalkyl compounds in the US population: data from the
619 National Health and Nutrition Examination Survey (NHANES) 1999–2000. *Environ Sci*
620 *Technol* 2007a;41:2237–2242
- 621 • Calafat AM, Wong LY, Kuklennyik Z, Reidy JA, Needham LL. Polyfluoroalkyl chemicals
622 in the U.S. Population: Data from the National Health and Nutrition Examination Survey
623 (NHANES) 2003-2004 and Comparisons with NHANES 1999-2000. *Environ Health*
624 *Perspect* 2007b;115(11):1596–1602
- 625 • Center for Disease Control and Prevention (CDC), 2009. U.S. Department of Health and
626 Human services. Fourth National Report on Human Exposure to Environmental
627 Chemicals. Accessed September 2014
- 628 ○ <http://www.cdc.gov/exposurereport/pdf/FourthReport.pdf>
- 629 • Center for Disease Control and Prevention (CDC), 2013. U.S. Department of Health and
630 Human services. Fourth National Report on Human Exposure to Environmental
631 Chemicals. Updated tables September 2013. Accessed September 2014

- 632 ○ [http://www.cdc.gov/exposurereport/pdf/FourthReport_UpdatedTables_Sep2013.p](http://www.cdc.gov/exposurereport/pdf/FourthReport_UpdatedTables_Sep2013.pdf)
633 df
- 634 • Chaemfa C, Barber JL, Huber S, Breivik K, Jones KC. Screening for PFOS and PFOA in
635 European air using passive samplers. *J Environ Monit* 2010;12:1100–1109
- 636 • Costa G, Sartori S, Consonni D. Thirty years of medical surveillance in perfluooctanoic
637 acid production workers. *J Occup Environ Med* 2009;51(3):364–372
- 638 • Dauwe T, Van de Vijver K, De Coen W, Eens M. PFOS levels in the blood and liver of a
639 small insectivorous songbird near a fluorochemical plant. *Environ Int* 2007;33:357-361
- 640 • D'Eon JC, Mabury SA. Is Indirect Exposure a Significant Contributor to the Burden of
641 Perfluorinated Acids Observed in Humans? *Environ Sci Technol* 2011;45:7974–7984
- 642 • Desborough J, Harrad S. Chiral Signatures Show Volatilization from Soil Contributes to
643 Polychlorinated Biphenyls in Grass, *Environ Sci Technol* 2011;45:7354-7357
- 644 • DeWitt JC, Peden-Adams MM, Keller JM, Germolec DR. Immunotoxicity of
645 Perfluorinated Compounds: Recent Developments. *J Toxicol Pathol* 2012;40:300-311
- 646 • D'Hollander W, de Voogt P, de Coen W, Bervoets L. Perfluorinated substances in human
647 food and other sources of human exposure. *Rev Environ Contam Toxicol* 2010;208:179–
648 215
- 649 • Dreyer A, Ebinghaus R. Polyfluorinated compounds in ambient air from ship- and land
650 based measurements in northern Germany. *Atmos Environ* 2009;43:1527–35
- 651 • Ericson I, Gomez M, Nadal M, van Bavel B, Lindstrom G, Domingo JL. Perfluorinated
652 chemicals in blood of residents in Catalonia (Spain) in relation to age and gender: a pilot
653 study. *Environ Int* 2007;33:616–623
- 654 • Ericson I, Nadal M, van Bavel B, Lindström G, Domingo JL. Levels of
655 perfluorochemicals in water samples from Catalonia, Spain: is drinking water a
656 significant contribution to human exposure? *Environ Sci Pollut Res* 2008;15:614–619

- 657 • Ericson I, Domingo JL, Nadal M, Bigas E, Llebaria X, van Bavel B, Lindström G. Levels
658 of Perfluorinated Chemicals in Municipal Drinking Water from Catalonia, Spain: Public
659 Health Implications. *Arch Environ Contam Toxicol* 2009;57:631–638
- 660 • Ericson Jogsten I, Nadal M, van Bavel B, Lindström G, Domingo JL. Per- and
661 polyfluorinated compounds (PFCs) in house dust and indoor air in Catalonia, Spain:
662 implications for human exposure. *Environ Int* 2012;39:172–80.
- 663 • Fletcher T, Galloway TS, Melzer D, Holcroft P, Cipelli R, Luke C, Pilling LC, Mondal D,
664 Luster M, Harries LW. Associations between PFOA, PFOS and changes in the expression
665 of genes involved in cholesterol metabolism in humans. *Environ Int* 2013;57-58:2–10
- 666 • Fromme H, Schlummer M, Möller A, Gruber L, Wolz G, Ungewiss J, Bohmer S, Dekant,
667 W, Mayer R, Liebl B, Twardella D. Exposure of an adult population to perfluorinated
668 substances using duplicate diet portions and biomonitoring data. *Environ Sci Technol*
669 2007a;41:7928–7933
- 670 • Fromme H, Midasch O, Twardella Y, Angerer J, Boehmer S, Liebl B. Occurrence of
671 perfluorinated substances in an adult German population in southern Bavaria. *Int Arch*
672 *Occup Environ Health* 2007b;80:313–319
- 673 • Fromme H, Tittlemier SA, Völkel W, Wilhelm M, Twardella D. Perfluorinated
674 compounds - Exposure assessment for the general population in western countries. *Int J*
675 *Hyg Environ Health* 2009;212:239–270
- 676 • Fromme H, Mosch C, Morovitz M, Alba-Alejandre I, Boehmer S, Kiranoglu M, Faber F.,
677 Hannibal I, Genzel-Boroviczény O, Koletzko B, Völkel W. Pre- and Postnatal Exposure
678 to Perfluorinated Compounds (PFCs). *Environ Sci Technol* 2010;44:7123–7129
- 679 • Gebbink WA, Letcher RJ. Linear and branched perfluorooctane sulfonate isomer patterns
680 in herring gull eggs from colonial sites across the Laurentian Great Lakes. *Environ Sci*
681 *Technol* 2010;44(10):3739–3745

- 682 • Gebbink WA, Berger U, Cousins IT. Estimating human exposure to PFOS isomers and
683 PFCA homologues: The relative importance of direct and indirect (precursor) exposure.
684 Environ Int 2015; 74: 160-169
- 685 • Geneva: Stockholm Convention Secretariat, 2009. Governments Unite to Step-up
686 Reduction on Global DDT Reliance and Add Nine New Chemicals Under International
687 Treaty. Stockhlo m Convention on Persistent Organic Pollutants (POPs). Accessed
688 September 2014
- 689 o <http://chm.pops.int/Convention/Pressrelease/COP4Geneva8May2009/tabid/542/language/en-US/Default.aspx>
- 690
- 691 • Genualdi S, Lee SC, Shoeib M, Gawor A, Ahrens L, Harner T. Global pilot study of
692 legacy and emerging persistent organic pollutants using sorbent-impregnated
693 polyurethane foam disk passive air samplers. Environ Sci Technol 2010;44:5534–9
- 694 • Goosey E, Harrad S. Perfluoroalkyl compounds in dust from Asian, Australian, European,
695 and North American homes and UK cars, classrooms, and offices. Environ Int
696 2011;37:86–92
- 697 • Goosey E, Harrad S. Perfluoroalkyl substances in UK indoor and outdoor air: Spatial and
698 seasonal variation, and implications for human exposure. Environ Int 2012;45:86–90
- 699 • Guerranti C, Perra G, Corsolini S, Focardi SE. Pilot study on levels of perfluorooctane
700 sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) in selected foodstuffs and
701 human milk from Italy. Food Chem 2013;140:197–203
- 702 • Guruge KS, Taniyasu S, Yamashita N, Wijeratna S, Mohotti KM, Seneviratne HR,
703 Kannan K, Yamakana N, Miyazaki S. Perfluorinated organic compounds in human blood
704 serum and seminal plasma: A study of urban and rural tea worker populations in Sri
705 Lanka (2005) J Environ Monit 2005;7(4):371-377

- 706 • Hansen KJ, Clemen LA, Ellefson ME, Johnson HO. Compound-specific, quantitative
707 characterization of organic fluorochemicals in biological matrices. *Environ Sci Technol*
708 2001;35:766–770
- 709 • Harada K, Saito N, Inoue K, Yoshinaga T, Watanabe T, Sasaki S, Kamiyama S, Koizumi
710 A. The influence of time, sex and geographic factors on levels of perfluorooctane
711 sulfonate and perfluorooctanoate in human serum over the last 25 years. *J Occup Health*
712 2004;46:141–147
- 713 • Harada K, Koizumi A, Saito N, Inoue K, Yoshinaga T, Date C, Fujii S, Hachiya N,
714 Hirosawa I, Koda S, Kusaka Y, Murata K, Omae K, Shimbo S, Takenaka K, Takeshita T,
715 Todoriki H, Wada Y, Watanabe T, Ikeda M. Historical and geographical aspects of the
716 increasing perfluorooctanoate and perfluorooctane sulfonate contamination in human
717 serum in Japan. *Chemosphere* 2007;66:293–301
- 718 • Haug LS, Thomsen C, Bechert G. Time trends and the influence of age and gender on
719 serum concentrations of perfluorinated compounds in archived human samples. *Environ*
720 *Sci Technol* 2009;43:2131–6
- 721 • Haug LS, Huber S, Schlabach M, Becher G, Thomsen C. Investigation on per- and
722 polyfluorinated compounds in paired samples of house dust and indoor air from
723 Norwegian homes. *Environ Sci Technol* 2011a;45:7991–7998
- 724 • Haug LS, Huber S, Becher G, Thomsen C. Characterisation of human exposure pathways
725 to perfluorinated compounds comparing exposure estimates with biomarkers of exposure.
726 *Environ Int* 2011b;37:687–693
- 727 • Herzke D, Huber S, Bervoets L, D'Hollander W, Hajslova J, Pulkrabova J, Brambilla G,
728 De Filippis SP, Klenow S, Heinemeyer G, de Voogt P. Perfluorinated alkylated
729 substances in vegetables collected in four European countries; occurrence and human
730 exposure estimations. *Environ Sci Pollut Res* 2013;20:7930–7939

- 731 • Hites RA. Polybrominated diphenyl ethers in the environment and in people: A meta-
732 analysis of concentrations. *Environ Sci Technol* 2004;38:945–956
- 733 • Hölzer J, Midash O, Rauchfuss K, Kraft M, Reupert R, Angerer J, Kleeschulte P,
734 Marschall N, Wilhelm M. Biomonitoring of perfluorinated compounds in children and
735 adults exposed to perfluorooctanoate- contaminated drinking water. *Environ Health*
736 *Perspect* 2008;116:651–657
- 737 • Houde M, Czub G, Small JM, Backus S, Wang X, Alaei M, Muir DC. Fractionation and
738 bioaccumulation of perfluorooctane sulfonate (PFOS) isomers in a Lake Ontario food
739 web. *Environ Sci Technol* 2008;42:9397–9403
- 740 • Hühnerfuss H, Shah MH. Enantioselective chromatography—A powerful tool for the
741 discrimination of biotic and abiotic transformation processes of chiral environmental
742 pollutants. *J Chromatogr A* 2009;1216:481–502
- 743 • Inoue K, Okada F, Ito R, Kato S, Sasaki S, Nakajima AU, Uno A, Saijo Y, Sata F,
744 Yoshimura Y, Kishi R, Nakazawa H. Perfluorooctane sulfonate (PFOS) and related
745 perfluorinated compounds in human maternal and cord blood samples: assessment of
746 PFOS exposure in susceptible population during pregnancy. *Environ Health Perspect*
747 2004;112:1204–1207
- 748 • Jahnke A, Huber S, Ternme C, Kylin H, Berger U. Development and application of a
749 simplified sampling method for volatile polyfluorinated alkyl substances in indoor and
750 environmental air. *J Chromatogr, A* 2007;1164(1–2):1–9
- 751 • Jin Y, Saito N, Harada KH, Inoue K, Koizumi A. Historical trends in human serum levels
752 of perfluorooctanoate and perfluorooctanesulphate in Shenyang, China Tohoku. *J Exp*
753 *Med* 2007;212:63–70
- 754 • Kadar H, Veyrand B, Barbarossa A, Pagliuca G, Legrand A, Boshier C, Boquien CY,
755 Durand S, Monteau F, Antignac JP, Le Bizec B. Development of an analytical strategy

756 based on liquid chromatography–high resolution mass spectrometry for measuring
757 perfluorinated compounds in human breast milk: Application to the generation of
758 preliminary data regarding perinatal exposure in France. *Chemosphere* 2011;85:473–480

- 759 • Kallenborn R, Hühnerfuss H. *Chiral Environmental Pollutants-Trace Analysis and*
760 *Ecotoxicology*. Springer; 2001 edition. ISBN 978-3-662-06243-2
- 761 • Kannan K, Corsolini S, Falandysz J, Fillmann K, Kumar KS, Loganathan BG, Mohd MA,
762 Olivero J, Van Wouwe N, Yang JH, Aldous KM. Perfluorooctanesulfonate and related
763 fluorochemicals in human blood from several countries. *Environ Sci Technol*
764 2004;38:4489–4495
- 765 • Kannan K, Tao L, Sinclair E, Pastva SD, Jude DJ, Giesy JP. Perfluorinated compounds in
766 aquatic organisms at various trophic levels in a Great Lakes food chain. *Arch. Environ.*
767 *Contam Toxicol* 2005;48 (4):559–566
- 768 • Kärman A, van Bavel B, Järnberg U, Hardell L, Lindström G. Perfluorinated chemicals
769 in relation to other persistent organic pollutants in human blood. *Chemosphere*
770 2006a;64:1582–1591
- 771 • Kärman A, Mueller JF, van Bavel B, Harden F, Toms LM, Lindström G. Levels of 12
772 perfluorinated chemicals in pooled Australian serum, collected 2002–2003, in relation to
773 age, gender, and region. *Environ Sci Technol* 2006b;40:3742–3748
- 774 • Kärman A, Ericson I, van Bavel B, Darnerud PO, Aune M, Glynn A, Lignell S,
775 Lindström G. Exposure of perfluorinated chemicals through lactation: levels of matched
776 human milk and serum and a temporal trend, 1996–2004, in Sweden. *Environ Health*
777 *Perspect* 2007a;115:226–30
- 778 • Kärman A, Langlois I, van Bavel B, Lindström G, Oehme M. Identification and pattern
779 of perfluorooctane sulfonate (PFOS) isomers in human serum and plasma. *Environ Int*
780 2007b;33(6):782–788

- 781 • Kärman A, Harada KH, Inoue K, Takasuga T, Ohi E, Koizumi A. Relationship between
782 dietary exposure and serum perfluorochemical (PFC) levels - A case study. *Environ Int*
783 2009;35:712–717
- 784 • Kärman A, Domingo JL, Llebaria X, Nadal M, Bigas E, van Bavel B, Lindström G.
785 Biomonitoring perfluorinated compounds in Catalonia, Spain: concentrations and trends
786 in human liver and milk samples. *Environ Sci Pollut Res Int* 2010;17(3):750–758
- 787 • Kato K, Calafat AM, Needham LL. Polyfluoroalkyl chemicals in house dust. *Environ Res*
788 2009;109:518–23
- 789 • Kato K, Wong LY, Jia LT, Kuklennyik Z, Calafat AM. Trends in exposure to
790 polyfluoroalkyl chemicals in the U.S. Population: 1999-2008. *Environ Sci Technol*
791 2011;45:8037–8045
- 792 • Kim SK, Kho YL, Shoeib M, Kim KS, Kim KR, Park JE, Shin YS. Occurrence of
793 perfluorooctanoate and perfluorooctanesulfonate in the Korean water system: Implication
794 to water intake exposure. *Environ Pollut* 2011a;159:1167-1173
- 795 • Kim SK, Lee KT, Kang CS, Tao L, Kannan K, Kim KR, Kim CK, Lee JS, Park PS, Yoo
796 YW, Ha JY, Shin YS, Lee JH. 2011b. Distribution of perfluorochemicals between sera
797 and milk from the same mothers and implications for prenatal and postnatal exposures.
798 *Environ Pollut* 2011b;159(1):169– 174
- 799 • Kissa E. *Fluorinated Surfactants and Repellents*, 2nd ed.; Marcel Dekker, Inc.: New York,
800 2001; Vol. 97, p 640
- 801 • Kubwabo C, Stewart B, Zhu J, Marro L. Occurrence of perfluorosulfonates and other
802 perfluorochemicals in dust from selected homes in the city of Ottawa, Canada. *J Environ*
803 *Monit* 2005;7:1074–8

- 804 • Kuklennyik Z, Reich JA, Tully LL, Needham LL, Calafat AM. Automated solid-phase
805 extraction and measurement of perfluorinated organic acids and amides in human serum
806 and milk. *Environ Sci Technol* 2004;38:3698–3704
- 807 • Lange FT, Wenz M, Schmidt CK, Brauch HJ. Occurrence of perfluoroalkyl sulfonates
808 and carboxylates in German drinking water sources compared to other countries. *Water*
809 *Sci Technol* 2007;56:151–158
- 810 • Lehmler HJ. Synthesis of environmentally relevant fluorinated surfactants—a review.
811 *Chemosphere* 2005;58:1471–1496
- 812 • Lehmler HJ, Harrad SJ, Hühnerfuss H, Kania-Korwel I, Lee CM, Lu Z, Wong CS. Chiral
813 polychlorinated biphenyl transport, metabolism, and distribution: A review. (2010)
814 *Environ Sci Technol* 2010;44 (8):2757-2766
- 815 • Lindstrom AB, Mark J, Strynar MJ, Libelo EL. Polyfluorinated Compounds: Past,
816 Present, and Future. *Environ Sci Technol* 2011;45:7954–7961
- 817 • Liu J, Li J, Zhao Y, Wang Y, Zhang L, Wu Y. The occurrence of perfluorinated alkyl
818 compounds in human milk from different regions of China. *Environ Int* 2010;36(5):433–
819 438
- 820 • Liu Y, Pereira AS, Beesoon S, Vestergren R, Berger U, Olsen GW, Glynn A, Martin JW.
821 Temporal trends of perfluorooctanesulfonate isomer and enantiomer patterns in archived
822 Swedish and American serum samples. *Environ Int* 2015;75:215-222
- 823 • Llorca M, Farre M, Pico Y, Teijon ML, Alvarez JG, Barcelo D. 2010. Infant exposure of
824 perfluorinated compounds: Levels in breast milk and commercial baby food. *Environ Int.*
825 2010;36(6):584–592
- 826 • Loos R, Wollgast J, Huber T, Hanke G. Polar herbicides, pharmaceutical products,
827 perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and nonylphenol and its

- 828 carboxylates and ethoxylates in surface and tap waters around Lake Maggiore in Northern
829 Italy. *Anal Bioanal Chem* 2007;387:1469–1478
- 830 • Loveless SE, Finlay C, Everds NE, Frame SR, Gillies PJ, O'Connor JC, Powley CR,
831 Kennedy GL. Comparative responses of rats and mice exposed to linear/branched, linear,
832 or branched ammonium perfluorooctanoate (APFO). *Toxicology* 2006;220:203–17
- 833 • Martin JW, Whittle DM, Muir DCG, Mabury SA. Perfluoroalkyl contaminants in a food
834 web from lake Ontario. *Environ Sci Technol* 2004;38 (20):5379–5385
- 835 • Martin JW, Asher BJ, Beesoon S, Benskin JP, Ross MS. PFOS or PreFOS? Are
836 perfluorooctane sulfonate precursors (PreFOS) important determinants of human and
837 environmental perfluorooctane sulfonate (PFOS) exposure? *J Environ Monit* 2010;12
838 11:1979–2004
- 839 • Midasch O, Schettgen T, Angerer J. Pilot study on PFOS and PFOA of the German
840 general population. *Int J Hyg Environ Health* 2006;209:489–496
- 841 • Midasch O, Drexler H, Hart N, Beckmann MW, Angerer J. Transplacental exposure of
842 neonates to perfluorooctanesulfonate and perfluorooctanoate: A pilot study. (2007) *Int*
843 *Arch Occup Environ Health* 2007;80(7):643-648
- 844 • Moriwaki H, Takatab Y, Arakawa R. Concentrations of perfluorooctane sulfonate (PFOS)
845 and perfluorooctanoic acid (PFOA) in vacuum cleaner dust collected in Japanese homes.
846 *J Environ Monit* 2003;5:753–757
- 847 • Mosch C, Kiranoglu M, Fromme H, Völkel W. Simultaneous quantitation of
848 perfluoroalkyl acids in human serum and breast milk using on-line sample preparation by
849 HPLC column switching coupled to ESI-MS/MS. *J Chromatogr B* 2010;878:2652–2658
- 850 • Nakata A, Katsumata T, Iwasaki Y, Ito R, Saito K, Izumi S, Makino T, Kishi R,
851 Nakazawa H, 2007. Measurement of perfluorinated compounds in human milk and house
852 dust. *Organohalogen Compd* 2007;69:2844–2846

- 853 • Nøst TH, Vestergren R, Berg V, Nieboer E, Odland JØ, Sandanger TM. Repeated
854 measurements of per- and polyfluoroalkyl substances (PFASs) from 1979 to 2007 in
855 males from Northern Norway: Assessing time trends, compound correlations and
856 relations to age/birth cohort. *Environ Int* 2014;67:43-53
- 857 • Olsen GW, Burriss JM, Burlew MM, Mandel JH. Epidemiologic assessment of worker
858 serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations
859 and medical surveillance examinations. *J Occup Environ Med* 2003;45:260–70
- 860 • Olsen GW, Huang HY, Helzlsouer KJ, Hansen KJ, Butenhoff JL, Mandel JH. Historical
861 comparison of perfluorooctanesulfonate, perfluorooctanoate, and other fluorochemicals in
862 human blood. *Environ Health Perspect* 2005;113:539–45
- 863 • Olsen GW, Burriss JM, Ehresman DJ, Froelich JW, Seacat AM, Butenhoff JL, Zobel LR.
864 Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and
865 perfluorooctanoate in retired fluorochemical production workers. *Environ Health Perspect*
866 2007a;115(9):1298–1305
- 867 • Olsen GW, Mair DC, Reagen WK, Ellefson ME, Ehresman DJ, Butenhoff JL, Zobel LR.
868 Preliminary evidence of a decline in perfluorooctanesulfonate (PFOS) and
869 perfluorooctanoate (PFOA) in American Red Cross blood donors. *Chemosphere*
870 2007b;68:105–111
- 871 • Olsen GW, Mair DC, Church TR, Ellefson ME, Reagen WK, Boyd TM, Herron RM,
872 Medhdizadehkashi Z, Nobiletti JB, Rios JA, Butenhoff JL, Zobel LR. Decline in
873 perfluorooctanesulfonate and other polyfluoroalkyl chemicals in American Red Cross
874 adult blood donors, 2000 - 2006. *Environ Sci Technol* 2008;42:4989–4995
- 875 • Olsen GW, Lange CC, Ellefson ME, Mair DC, Church TR, Goldberg CL, et al. Temporal
876 trends of perfluoroalkyl concentrations in American Red Cross adult blood donors, 2000–
877 2010. *Environ Sci Technol* 2012;46:6330–6338

- 878 • Paul AG, Jones KC, Sweetman AJ. A first global production, emission, and
879 environmental inventory for perfluorooctane sulfonate. *Environ Sci Technol*
880 2009;43(2):386–392
- 881 • Prevedouros K, Cousins IT, Buck RC, Korzeniowski SH. Sources, fate and transport of
882 perfluorocarboxylates. *Environ Sci Technol* 2006;40:32–44
- 883 • Renner R. The long and the short of perfluorinated replacements. *Environ Sci Technol*
884 2006;40:12–13
- 885 • Riddell N, Arsenault G, Benskin JP, Chitti B, Martin JW, McAlees A, McCrindle R.
886 Branched perfluorooctane sulfonate isomer quantification and characterization in blood
887 serum samples by HPLC/ESI-MS(/MS). *Environ Sci Technol* 2009;43(20):7902–7908
- 888 • Robson M, Harrad S. Chiral PCB signatures in air and soil: Implications for atmospheric
889 source apportionment. *Environ Sci Technol* 2004;38:1662–1666
- 890 • Roosens L, D'Hollander W, Bervoets L, Reynders H, Van Campenhout K, Cornelis C,
891 Van Den Heuvel R, Koppen G, Covaci A. (2010). Brominated flame retardants and
892 perfluorinated chemicals, two groups of persistent contaminants in Belgian human blood
893 and milk. *Environ Pollut* 2010;158:2546–2552
- 894 • Ross MS, Wong CS, Martin JW. Isomer-Specific Biotransformation of Perfluorooctane
895 Sulfonamide in Sprague–Dawley Rats. *Environ Sci Technol* 2012;46:3196–3203
- 896 • Saito N, Harada K, Inoue K, Sasaki K, Yoshinaga T, Koizumi A. Perfluorooctanoate and
897 perfluorooctane sulfonate concentrations in surface water in Japan. *J Occup Health*
898 2004;46:49–59
- 899 • Sakr CJ, Leonard RC, Kreckmann KH, Slade MD, Cullen MR. Longitudinal study of
900 serum lipids and liver enzymes in workers with occupational exposure to ammonium
901 perfluorooctanoate. *J Occup Environ Med* 2007;49(8):872–879

- 902 • Scheringer M, Vögl T, von Grote J, Capaul B, Schubert R, Hungerbühler K. (2001).
903 Scenario-based risk assessment of multi-use chemicals: Application to solvents. *Risk*
904 *Anal* 2001;21(3):481–497
- 905 • Schultz M, Barofsky D, Field J. Fluorinated Alkyl Surfactants. *Environ Eng Sci*.
906 2003;20(5):487-501
- 907 • Seacat AM, Thomford PJ, Hansen KJ, Clemen LA, Eldridge SR, Elcombe CR, Butenhoff
908 JL. Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats.
909 *Toxicology* 2003;183:117–31
- 910 • Sharpe RL, Benskin JP, Laarman AH, MacLeod SL, Martin JW, Wong CS, Goss GG.
911 Perfluorooctane sulfonate toxicity, isomer-specific accumulation, and maternal transfer in
912 zebrafish (*Danio rerio*) and rainbow trout (*Oncorhynchus mykiss*). *Environ Toxicol Chem*
913 2010;29(9):1957–1966
- 914 • Shoeib M, Harner T, Wilford BH, Jones KC, Zhu JP. Perfluorinated sulfonamides in
915 indoor and outdoor air and indoor dust: Occurrence, partitioning, and human exposure.
916 *Environ Sci Technol* 2005;39(17):6599–6606
- 917 • Shoeib M, Harner T, Webster GM, Lee SC. Indoor sources of poly- and perfluorinated
918 compounds (PFCs) in Vancouver, Canada: implications for human exposure. *Environ Sci*
919 *Technol* 2011;45:7999–8005
- 920 • Skutlarek D, Exner M, Färber H. Perfluorinated Surfactants in Surface and Drinking
921 Waters. *Environ Sci Pollut Res* 2006;13(5):299–307
- 922 • So MK, Yamashita N, Taniyasu S, Jiang Q, Giesy JP, Chen K, Lam PKS. Health risks in
923 infants associated with exposure to perfluorinated compounds in human breast milk from
924 Zhoushan. China. *Environ Sci Technol* 2006;40(9):2924–2929

- 925 • Sonne C. Health effects from long-range transported contaminants in Arctic top
926 predators: an integrated review based on studies of polar bears and relevant model
927 species. *Environ Int* 2010;36:461–491
- 928 • Steenland K, Fletcher T, Savitz DA. Epidemiologic evidence on the health effects of
929 perfluorooctanoic acid (PFOA). *Environ Health Perspect* 2010;118(8):1100–1108
- 930 • Strynar MJ, Lindstrom AB. Perfluorinated compounds in house dust from Ohio and North
931 Carolina, USA. *Environ Sci Technol* 2008;42:3751–6
- 932 • Sundström M, Ehresman DJ, Bignert A, Butenhoff JL, Olsen GW, Chang SC, Bergman
933 A. A temporal trend study (1972–2008) of perfluorooctanesulfonate,
934 perfluorohexanesulfonate, and perfluorooctanoate in pooled human milk samples from
935 Stockholm, Sweden. *Environ Int* 2011;37:178–183
- 936 • Takagi S, Adachi F, Miyano K, Koizumi Y, Tanaka H, Mimura M, Watanabe I, Tanabe
937 S, Kannan K. Perfluorooctanesulfonate and perfluorooctanoate in raw and treated tap
938 water from Osaka, Japan. *Chemosphere* 2008;72:1409–1412
- 939 • Tanaka S, Fujii S, Lien NPH, Nozoe M, Chinagarn K, Kimura K, Shivakoti B, Anton A,
940 Maketab M, Wirojanagud W, Hu JY, Kitpati S, Shimizu J, Tittlemier S, Lindström G,
941 Saito N. Contamination of perfluorinated compounds in water environment of Asian
942 countries. *Organohalogen Compd* 2008;70:402–405
- 943 • Taniyasu S, Kannan K, Horii Y, Hanari N, Yamashita N. A survey of perfluorooctane
944 sulfonate and related perfluorinated organic compounds in water, fish, birds, and humans
945 from Japan. *Environ Sci Technol* 2003;37:2634–2639
- 946 • Tao L, Ma J, Kunisue T, Libelo EL, Tanabe S, Kannan K. Perfluorinated compounds in
947 human breast milk from several Asian countries, and in infant formula and dairy milk
948 from the United States. *Environ Sci Technol* 2008;42(22):8597–8602

- 949 • Taves DR. Determination of submicromolar concentrations of fluoride in biological
950 samples. *Talanta* 1968;15:1015-1023
- 951 • Thomsen C, Haug L, Stigum H, Frøshaug M, Broadwell SL, Becher G. Changes in
952 Concentrations of Perfluorinated Compounds, Polybrominated Diphenyl Ethers, and
953 Polychlorinated Biphenyls in Norwegian Breast-Milk during Twelve Months of
954 Lactation. *Enviro. Sci Technol* 2010;44:9550–9556
- 955 • Tittlemier SA, Pepper K, Edwards L. Concentrations of perfluorooctanesulfonamides in
956 Canadian total diet study composite food samples collected between 1992 and 2004. *J*
957 *Agric Food Chem* 2006;54:8385–8389
- 958 • Tomy GT, Tittlemier SA, Palace VP, Budakowski WR, Braekevelt E, Brinkworth L,
959 Freisen K. Biotransformation of N-ethyl perfluorooctanesulfonamide by rainbow trout
960 (*Onchorhynchus mykiss*) liver microsomes. *Environ Sci Technol* 2004;38:758–762
- 961 • Trudel D, Horowitz L, Wormuth M, Scheringer M, Cousins IT, Hungerbuhler K.
962 Estimating consumer exposure to PFOS and PFOA. *Risk Anal* 2008;28:251–269
- 963 • Ullah S, Hube S, Bignert A, Berger U. Temporal trends of perfluoroalkane sulfonic acids
964 and their sulfonamide-based precursors in herring from the Swedish west coast 1991–
965 2011 including isomer-specific considerations. *Environ Int* 2014;65: 63–72
- 966 • UNEP, United Nations Environmental Programme. The 9 New POPs: An Introduction to
967 the Nine Chemicals Added to the Stockholm Convention by the Conference of the Parties
968 at its Fourth Meeting, 2010
- 969 ○ www.pops.int/
- 970 • USEPA. Provisional Health Advisories for Perfluorooctanoic Acid (PFOA) and
971 Perfluorooctane Sulfonate (PFOS); U.S. Environmental Protection Agency: Washington,
972 DC, January 8, 2009. Accessed September 2014

- 973 ○ [http://www.epa.gov/opptintr/pfoa/pubs/Final%20PFOA%20PFOS%20RfD%20m](http://www.epa.gov/opptintr/pfoa/pubs/Final%20PFOA%20PFOS%20RfD%20memo%2010-28-09.pdf)
- 974 [emo%2010-28-09.pdf](http://www.epa.gov/opptintr/pfoa/pubs/Final%20PFOA%20PFOS%20RfD%20memo%2010-28-09.pdf)
- 975 • USEPA 2010/15 PFOA Stewardship Program. Accessed September 2014
- 976 ○ <http://www.epa.gov/oppt/pfoa/pubs/stewardship/index.htm>
- 977 • Vestergren R, Cousins IT, Trudel D, Wormuth M, Scheringer M. Estimating the
- 978 contribution of precursor compounds in consumer exposure to PFOS and PFOA.
- 979 Chemosphere 2008;73:1617–1624
- 980 • Völkel W, Genzel-Boroviczeny O, Demmelmair H, Gebauer C, Koletzko B, Twardella D,
- 981 Raab U, Fromme H. 2008. Perfluorooctane sulphonate (PFOS) and perfluorooctanoic
- 982 acid (PFOA) in human breast milk: results of a pilot study. Int J Hyg Environ Health
- 983 2008;211(3–4):440–446
- 984 • Wang Y, Yeung LWY, Taniyasu S, Yamashita N, Lam JCW, Lam PKS. Perfluorooctane
- 985 Sulfonate and Other Fluorochemicals in Waterbird Eggs from South China. Environ Sci
- 986 Technol 2008;42:8146–8151
- 987 • Wang Y, Arsenault G, Riddell N, McCrindle R, McAlees A, Martin JW. Perfluorooctane
- 988 sulfonate (PFOS) precursors can be metabolized enantioselectively: Principle for a new
- 989 PFOS source tracking tool. Environ Sci Technol 2009;43(21):8283–8289
- 990 • Wang Y, Beesoon S, Benskin JP, De Silva AO, Genuis SJ, Martin JW. Enantiomer
- 991 fractions of chiral perfluorooctanesulfonate (PFOS) in human sera. Environ Sci Technol
- 992 2011;45(20):8907–8914
- 993 • Wilhelm M, Angerer J, Fromme H, Hölzer J. Contribution to the evaluation of reference
- 994 values for PFOA and PFOS in plasma of children and adults from Germany. Int J Hyg
- 995 Environ Health 2009;212:56–60
- 996 • Xie W, Wu Q, Kania-Korwel I, Tharappel JC, Telu S, Coleman MC, Glauert HP, Kannan
- 997 K, Mariappam SVS, Spitz D, Weydert J, Lehmler HJ. Subacute exposure to N-ethyl

998 perfluorooctanesulfonamido ethanol results in the formation of perfluorooctanesulfonate
999 and alters superoxide dismutase activity in female rats. *Arch Toxicol* 2009;83:909–924

1000 • Xu L, Krenitsky DM, Seacat AM, Butenhoff JL, Anders MW. Biotransformation of N-
1001 ethyl-N-(2-hydroxyethyl)perfluorooctanesulfonamide by rat liver microsomes, cytosol,
1002 and slices and by expressed rat and human cytochromes P450. *Chem Res Toxicol*
1003 2004;17:767–775

1004 • Yeung LW, So MK, Jiang G, Taniyasu S, Yamashita N, Song M, Wu Y, Li J, Giesy JP,
1005 Guruge KS, Lam PKS. 2006. Perfluorooctanesulfonate and related perfluorochemicals in
1006 human blood samples from China. *Environ Sci Technol* 2006;40:715–720

1007 • Zhang Y, Beesoon S, Zhu L, Martin JW. Isomers of perfluorooctanesulfonate and
1008 perfluorooctanoate and total perfluoroalkyl acids in human serum from two cities in
1009 North China. *Environ Int* 2013;53:9–17

1010 • Zhao YG, Wong CKC, Wong MH. Environmental contamination, human exposure and
1011 body loadings of perfluorooctane sulfonate (PFOS), focusing on Asian countries.
1012 *Chemosphere* 2012;89:355–368

1013 • Zushi Y, Hogarh JN, Masunaga S. Progress and perspective of perfluorinated compound
1014 risk assessment and management in various countries and institutes. *Clean Techn Environ*
1015 *Policy* 2012;14:9–20

1016

Table 1. Comparison of reported PFOS concentrations and ranges in human blood or serum (ng/mL)

Authors	Year	Country	Matrix	n	% DF	Mean	Median ^c	Range
Ericson et al.	2007	Spain	Whole blood	48	100	7.64	7.6	0.76-16.2
Fromme et al. (b)	2007	Germany	Plasma	356	100	13.5	13.7	2.1-55.0
Hansen et al.	2001	USA	Serum	65	100	25.519	25.7	6.7-81.5
Haug et al. (b)	2011	Norway	Serum	41	100	6.9	NR	2.3-15.0
Hölzer et al.	2008	North Rhine	Plasma	80	NR	NR	4.3	1.5-26.2
Jin et al.	2007	China	Serum	119	NR	NR	22.4	0.2-145.0
Kannan et al.	2004	USA	Serum	46/29 ^d	91/93 ^d	32.5/32.9 ^d	28.9/26.2 ^d	<1.3-124
		USA	Whole blood	11/19 ^d	100/100 ^d	66/73.2 ^d	81/72 ^d	11-164
		USA	Plasma	70	100	42.8	42	16-83
		Colombia	Whole blood	25/31 ^d	100/100 ^d	8.0/8.5 ^d	7.3/8.1 ^d	4.6-14
		Brazil	Whole blood	17/10 ^d	100/100 ^d	10.7/13.5 ^d	8.4/12.7 ^d	4.3-35
		Italy	Serum	8/42 ^d	87.5/90.5 ^d	4.4/4.3 ^d	3.5/4.2 ^d	<1-10.3
		Poland	Whole blood	15/10 ^d	100/100 ^d	33.3/55.4 ^d	33.8/40.9 ^d	16.0-116
		Belgium	Plasma	4/16 ^d	100/100 ^d	11.1/16.8 ^d	10.4/17.6 ^d	4.5-27.0
		India	Serum	11/34 ^d	55/50 ^d	2.3/1.7 ^d	2.5/1.3 ^d	<1-3
		Malaysia	Whole blood	7/16 ^d	100/100 ^d	11.7/13.2 ^d	12.7/13.1 ^d	6.2-18.8
		Korea	Whole blood	25/25 ^d	100/100 ^d	15.1/27.1 ^d	11.3/18.3 ^d	3.0-92

		Japan	Serum	13/25 ^d	100/100 ^d	20.1/14.1 ^d	18.3/12.4 ^d	4.1-40.3
Kärrman et al. (a)	2006	Sweden	Whole blood	66	100	16	17.1	1.7-37.0
Kärrman et al. (b)	2006	Australia	Serum	40	NR	21.3	20.8	12.7-29.5
Kärrman et al. (a)	2007	Sweden	Serum	12	100	20.7	18.7	8.2-48.0
Kato et al.	2011	USA	Serum (years 99-00)	1562	100	30.4	NR	NR
(NHANES reports			Serum (years 03-04)	2094	99.9	20.7	NR	NR
overview). Calafat et			Serum (years 05-06)	2120	99.9	17.1	NR	NR
al. (2007) (a) (b)			Serum (years 07-08)	2100	99.8	13.2	NR	NR
Midash et al.	2006	Germany	Plasma	105	100	NR	22.3	6.2-131.0
Olsen et al.	2005	USA	Serum	178	NR	30.1	29.5	NR
			Plasma	178	NR	33.3	34.7	NR
Yeung et al.	2006	China	Serum	85	NR	NR	52.7	NR

c) For concentrations <LOQ, the value was assumed to = 1/2 LOQ. d) Separate female/male data reported for this study.

DF: Detection frequency. NR: Not reported.

Table 2. Comparison of reported PFOS concentrations and ranges in human breast milk (ng/mL)

Authors	Year	Country	n	% DF	Mean	Median^c	Range
Antignac et al.	2013	France	48	90	0.092	0.075	<0.050-0.330
Bernsmann and Fürst	2008	Germany	203	66	NR	0.082	0.05-0.284
Fromme et al.	2010	Germany	201	72	NR	0.040	<0.030-0.110
Guerranti et al.	2013	Italy	49	41	0.85	NR	<1.020-4.280
Haug et al. (b)	2011	Norway	19	100	0.093	0.087	0.004-0.250
Kadar et al.	2011	France	30	100	NR	0.074	0.024-0.171
Kärrman et al. (a)	2007	Sweden	12	100	0.201	0.121	0.063-0.465
Kärrman et al.	2010	Spain	10	100	0.12	0.110	0.070-0.220
Kim et al. (b)	2011	Korea	17	100	0.061	NR	0.032-0.130
Liu et al.	2010	China	24	100	0.046	0.049	0.006-0.137
Llorca et al.	2010	Spain	20	95	0.071	0.084	0.028-0.865
Mosch et al.	2010	Germany	20	95	NR	0.049	<0.030-0.195
Nakata et al.	2007	Japan	51	100	NR	NR	0.008-0.401
Roosens et al.	2010	Belgium	22	NR	NR	2.900	<0.400-28.2
So et al.	2006	China	19	100	0.105	0.100	0.045-0.360
Sundstrom et al.	2011	Sweden	20 ^d	100	0.156	0.206	0.088-0.151

Tao et al.	2008	USA	45	96	NR	0.106	<0.032-0.617
		Cambodia	24	100	0.067	0.040	0.017-0.327
		Vietnam	40	100	0.076	0.058	0.017-0.393
		Indonesia	20	100	0.084	0.067	0.025-0.256
		Philippines	24	100	0.098	0.104	0.027-0.208
		Malaysia	13	100	0.121	0.111	0.049-0.350
		India	39	85	0.046	0.039	<0.011-0.120
		Japan	24	100	0.232	0.196	0.140-0.523
Thomsen et al.	2010	Norway	68	NR	NR	0.110	0.028-0.36
Völkel et al.	2008	Germany	19	100	0.116	0.113	0.028-0.239
		Germany	38	100	0.126	0.123	0.033-0.309
		Hungary	13	100	0.317	0.330	0.096-0.639

c) For concentrations <LOQ, the value was assumed = 1/2 LOQ. d) 20 pools of human milk.

DF: Detection frequency. NR: Not reported.

Table 3. Comparison of reported PFOS concentrations and ranges (ng/L) in drinking water

Authors	Year	Country	n	% DF	A/GM	Median ^c	Range
Ericson et al.	2008	Spain	4	100	0.57 ^c (GM)	0.59	0.39-0.87
Ericson et al.	2009	Spain	40	87	3.72 (GM)	0.51	<0.12-58.12
Kim et al.(a)	2011	Korea	15	NR	NR	NR	<0.33-11.00
Loos et al.	2007	Italy	6	100	8.1 (A)	NR	6.20-9.70
Saito et al.	2004	Japan	30	67	0.7-12.5 ^d (GM)	0.65	<0.10-12.00
Skutlarek et al.	2006	Germany	37	35	2.09 ^c (GM)	1.00	<1.00-22.00
Takagi et al.	2008	Japan	26	96	1.51 (GM)	1.90	<0.16-22.00
Tanaka et al.	2008	Japan	NR	NR	NR	NR	<0.01-143.0

c) For concentrations <LOQ, the value was assumed = 1/2 LOQ. b) Estimated in 6 different areas.

DF: Detection frequency. A: Average. GM: Geometric mean. NR: Not reported.

Table 4. Comparison of reported PFOS concentrations and ranges in indoor dust (ng/g)

Authors	Year	Country/Microenvironment		Source	n	% DF	Average	Median ^c	Range
		Category							
Bjorklund et al.	2009	Sweden / Houses	Dust	10	100	49.0 ^d	39.0	15-120	
		Sweden / Apartments	Dust	38	79	175.0 ^d	85.0	<8.0-1100	
		Sweden / Offices	Dust	10	100	144.0 ^d	110.0	29-490	
		Sweden / Daycare centres	Dust	10	100	38.0 ^d	31.0	23-65	
		Sweden / Cars	Dust	5	60	18.0 ^d	12.0	<8.0-33	
Ericson Jogsten et al.	2012	Spain / Houses	Dust	10	100	2.1	2.2	0.13-12.0	
Goosey and Harrad	2011	UK / Cars	Dust	20	100	132.0	97.0	20-1500	
		UK / Classrooms	Dust	42	100	640.7	980.0	22-3700	
		UK / Houses	Dust	45	100	144.7	450.0	3.5-7400	
		UK / Offices	Dust	20	100	182.5	370.0	20-1000	
		Australia / Houses	Dust	20	100	187.0	170.0	6.5-8100	
		Canada / Houses	Dust	19	100	157.8	140.0	42-1300	
		France / Houses	Dust	10	100	193.8	160.0	54-1700	
		Germany / Houses	Dust	10	100	188.9	170.0	47-1000	
Kazakhstan / Houses	Dust	9	80	12.5	59.0	<0.03-130			

		Thailand / Houses	Dust	20	100	19.5	16.0	3-130
		USA / Houses	Dust	10	100	318.1	310.0	110-930
Kato et al.	2009	Australia / Houses	Dust	39	74	NR	480.0	<2.6-18000
Kubwabo et al.	2005	Canada / Houses	Dust	67	67	443.7	37.8	2.3-5065
Moriwaki et al.	2003	Japan / Houses	Dust	16	100	39.5	25.0	15.0-2500
Strynar et al.	2008	USA / Houses (102) and child daycare centres (10)	Dust	112	95	761.0	201.0	<8.9-12100

c) For concentrations <LOQ, the value was assumed = 1/2 LOQ d) Arithmetic mean.

DF: Detection frequency. NR: Not reported.

Table 5. Comparison of reported PFOS concentrations and ranges in indoor and outdoor air (pg/m³)

Authors	Year	Country	Source	n	% DF	Mean	Median ^c	Range
Barber et al.	2007	Norway	Indoor air	4	0	NR	NR	<47.4
Ericson Jogsten et al.	2012	Spain	Indoor air	10	33	0.3	0.1	<0.13-67.0
Goosey and Harrad	2012	UK	Indoor air	20	90	12.4	11.5	<1.0-400.0
		UK	Indoor air	12	100	49.4	55.0	12.0-89.0
Shoeib et al.	2011	Canada	Indoor air	39	0	<LOD	<LOD	<LOD
Barber et al.	2007	UK	Outdoor air	2	NR	NR	NR	46
		UK	Outdoor air	10	NR	NR	NR	1.6
Dreyer et al.	2009	Germany	Outdoor air	117	0	<LOD	<LOD	<LOD
		Germany	Outdoor air	121	0	<LOD	<LOD	<LOD
Genualdi et al.	2010	Diff.	Outdoor air	20	50	NR	NR	2.03-149.5
		Countries						
Goosey and Harrad	2012	UK	Outdoor air	10	70	1.5	1.6	<0.1-6.1
Shoeib et al.	2011	Canada	Outdoor air	6	0	<LOD	<LOD	<LOD

c) For concentrations <LOQ, the value was assumed = 1/2 LOQ.

DF: Detection frequency. NR: Not reported.

Table 6. List of PFOS, its salts and its main precursors

CAS number	Common name	Systematic name	Molecular formula
N/A	PFOS anion	1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-hepta-decafluoro-1-Octanesulfonate	$C_8F_{17}SO_3^-$
	PFOS acid		
1763-23-1	(perfluorooctanesulfonic acid)	1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-hepta-decafluoro-1-Octanesulfonic acid	$C_8F_{17}SO_3H$
2795-39-3	PFOS potassium (K^+) salt	1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-hepta-decafluoro-1-Octanesulfonic acid, potassium salt	$C_8F_{17}SO_3K$
29081-56-9	PFOS ammonium (NH_4^+) salt	1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-hepta-decafluoro-1-Octanesulfonic acid, ammonium salt	$C_8F_{17}SO_3NH_4$
29457-72-5	PFOS lithium (Li^+) salt	1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-hepta-decafluoro-1-Octanesulfonic acid, lithium salt	$C_8F_{17}SO_3Li$
70225-14-8	PFOS diethanolamine (DEA) salt	1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-hepta-decafluoro-1-Octanesulfonic acid, compd. with 2,2-iminobis[ethanol] (1:1)	$C_8F_{17}SO_3NH(CH_2CH_2OH)_2$
307-35-7	POSF	1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-hepta-decafluoro-1-Octanesulfonyl fluoride	$C_8F_{18}O_2S$
1691-99-2	N-EtFOSE alcohol	N-ethyl-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-hepta-decafluoro-N-(2-hydroxyethyl)-1-Octanesulfonamide	$C_{12}H_{10}F_{17}NO_3S$

4151-50-2	N-EtFOSA	N-ethyl-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro-1-Octanesulfonamide	$C_{10}H_6F_{17}NO_2S$
24448-09-7	N-MeFOSE alcohol	1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro-N-(2-hydroxyethyl)-N-methyl-1-Octanesulfonamide	$C_{11}H_8F_{17}NO_3S$
31506-32-8	N-MeFOSA	1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro-N-methyl-1-Octanesulfonamide	$C_9H_4F_{17}NO_2S$
25268-77-3	N-MeFOSEA	2-Propenoic acid, 2-[[heptadecafluorooctyl)sulfonyl]methylamino]ethyl ester	$C_{14}H_{10}F_{17}NO_4S$
423-82-5	N-EtFOSEA	2-Propenoic acid, 2-[ethyl[(heptadecafluorooctyl)sulfonyl]amino]ethyl ester	$C_{15}H_{12}F_{17}NO_4S$

Table 7. Linear versus branched chain composition profiles and enantiomer fractions (EFs) of PFOS and its precursors in various matrices

Authors	Year	Country	Study	Matrix	n	Analytes
Asher et al.	2012	Canada	Lake	Aquatic Species	67	PFOSA (\approx 57% linear)
						PFOS (>90% linear)
				Water	2	PFOS (70% linear)
				Sediment	3	PFOS (>90% linear)
Beesoon et al.	2011	Canada	Human	Dust	18	PFOS (\approx 70% linear)
				Serum	20	PFOS (\approx 64% linear)
				Cord serum	20	PFOS (\approx 54% linear)
Benskin et al.	2007	Canada	Human	Serum	14	PFOS (\approx 80% linear)
Haug et al.	2009	Norway	Human	Serum	57	PFOS (53-78 linear)
Houde et al.	2008	Canada	Niagara/Lake	Fish	22	PFOS (88-93% linear)
				Water	NR	PFOS (43-56 linear)
Kärroman et al. (b)	2007	Sweden	Human	Serum/blood	17	PFOS (68% linear)
		UK			13	PFOS (59% linear)
		Australia			40	PFOS (59% linear)
Ross et al.	2012	Canada	Animals	Blood	8	PFOSA (\approx 78% linear)
				Blood	8	PFOS (\approx 77% linear)

				Heart	8	PFOSA (\approx 93% linear)
				Fat	8	PFOSA (\approx 86% linear)
Sharpe et al.	2010	Canada	-	Fish	NR	PFOS (>70% linear)
Wang et al.	2011	Canada	Animals	Rats	3	1m-PFOS (EF \approx 0.5)
			Human	Serum	8	1m-PFOS (EF=0.43)
			Human	Serum	7	1m-PFOS (EF=0.35-0.43)
Zhang et al.	2013	China	Human	Serum	129	PFOS (48% linear)

NR: Not reported.




Fig. 1. PFOS K salt, PFOSA, and POSF structures




Fig 2. Linear PFOS structure (named as n-PFOS) and monomethylated PFOS branched isomers, where the chiral carbon is represented by *. Each isomer containing a chiral centre has 2 enantiomers (R and S)